Chapter 7

Resource Compendium and Regulatory References

Global Safety Databases

WHO-UMC

VigiBase

The world's largest repository of individual case safety reports. Primary tool for identifying extremely rare adverse events across global populations.

20M+ reports from 150+ countries
EMA

EudraVigilance

The centralized EU database for adverse reaction reports. Critical for signal detection within the European Economic Area (EEA).

EU/EEA centralized reporting hub
FDA

FAERS

The US repository for adverse event reports, medication errors, and product quality complaints. Publicly accessible for data mining.

US adverse events + medication errors

Regulatory Organizations & Key Documents

WHO
VigiBase WHO-UMC Causality Scale Programme for International Drug Monitoring
ICH
E2A (Definitions) E2B(R3) (Electronic ICSR) E2C(R2) (PBRER) E2D (Post-Approval) E2E (PV Planning)
EMA / EU
GVP Modules I–XVI EudraVigilance PRAC SmPC
FDA
FAERS MedWatch IND Safety Reports USPI
CIOMS
CIOMS I Form Working Groups I–XI Signal Detection Guidelines

Essential ICH Guidelines

E2A

Clinical Safety Data Management

Definitions and standards for expedited reporting of adverse drug reactions

E2B(R3)

Electronic Transmission of ICSRs

Data elements and message specification for electronic safety reporting (HL7-based)

E2C(R2)

Periodic Benefit-Risk Evaluation

PBRER format and content requirements for periodic aggregate safety assessment

E2D

Post-Approval Safety Reporting

Standards for safety data reporting after marketing authorization is granted

E2E

Pharmacovigilance Planning

Framework for proactive safety surveillance planning throughout the product lifecycle

E2F

Development Safety Update Report

DSUR format for annual safety reporting during clinical development

GVP Modules Overview

I

PV System & PSMF

System requirements and master file

II

PSMF Content

Detailed content requirements

III

PV Inspections

Regulatory inspection framework

IV

PV Auditing

Internal audit standards

V

Risk Management

Risk Management Plans (RMPs)

VI

ICSRs & Reporting

Case management and reporting

VII

PBRER

Periodic safety update reports

VIII

Post-Authorization Studies

PASS and safety studies

IX

Signal Management

Detection, validation, evaluation

X

Additional Monitoring

Enhanced surveillance activities

XV

Safety Communication

DHPCs and risk communication

XVI

Risk Minimization

Measures to reduce risk in practice

Emerging Trends: AI-Powered Pharmacovigilance

75%

Real-World Data Adoption

Of pharmaceutical firms reported using Real-World Data (RWD) in drug development by 2025

47%

Random Forest Usage

Of AI pharmacovigilance studies utilize Random Forest algorithms for signal detection

Agentic AI

Autonomous Prioritization

Systems that autonomously prioritize and triage incoming safety reports, reducing human workload on low-risk cases

The Future of PV

AI and Machine Learning are being integrated into safety systems to autonomously prioritize incoming reports, detect patterns in large datasets, and augment traditional statistical methods. The combination of real-world data with spontaneous reporting is creating a more comprehensive safety surveillance ecosystem.